Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
I-131 iodocholesterol (131I-19-iodocholesterol) is a radiopharmaceutical diagnostic agent developed for the visualization of the adrenal cortex. It consists of cholesterol labeled with the radioisotope iodine-131. As cholesterol is a primary precursor for steroid hormone synthesis, the radiotracer is taken up by the adrenal glands via lipoprotein receptors, primarily the low-density lipoprotein (LDL) receptor. Once accumulated, the gamma emissions from I-131 allow for scintigraphic imaging (gamma imaging) to evaluate adrenal function and detect abnormalities such as Cushing's syndrome, primary hyperaldosteronism, and adrenal neoplasms (adenomas and carcinomas). While it was a pioneering agent in adrenal imaging, it was largely superseded by the second-generation agent NP-59 (131I-6β-iodomethyl-19-norcholesterol) due to the latter's higher adrenal avidity and lower background interference.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on I-131 iodocholesterol.